GO:0048550 negative regulation of pinocytosis: Cellular Uptake Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0048550 (negative regulation of pinocytosis) describes any process that stops, prevents, or reduces the frequency, rate, or extent of pinocytosis, the 'cell drinking' uptake of extracellular fluid.
• Pinocytosis and the related process macropinocytosis are hijacked by cancer cells for nutrient acquisition and metabolic reprogramming, making their negative regulation therapeutically relevant.
• Signaling nodes such as PI3K/PTEN, Akt3, p21-activated kinase-1 (PAK1), and mTORC1 act as brakes or drivers on fluid-phase uptake, and their perturbation alters pinocytic flux.
• The endolysosomal transporter Spns1 is required for megalin-dependent endocytosis, linking lysosomal lipid/iron handling to the endocytic machinery that pinocytosis feeds.
• Negative regulation of pinocytosis is studied with CRISPR knockout, point-mutation, knock-in, and overexpression models combined with live imaging, proteomics, and CRISPR library screening.
• Dysregulated fluid-phase uptake contributes to cancer, metabolic disease, and renal endocytic disorders, so restoring or blocking pinocytosis is an active therapeutic strategy.
Description
GO:0048550, negative regulation of pinocytosis, is a biological_process term in the Gene Ontology that captures any mechanism which stops, prevents, or reduces the frequency, rate, or extent of pinocytosis. Pinocytosis is the process by which cells take in liquid material from their external environment, literally 'cell drinking'; liquid is enclosed in vesicles formed by invagination of the plasma membrane, and these vesicles then move into the cell and pass their contents to endosomes. Because fluid-phase uptake supplies nutrients, lipids, and signaling molecules, its negative regulation sits at the intersection of nutrient sensing, membrane trafficking, and cell growth control. For researchers, GO:0048550 matters because pinocytosis and its close relative macropinocytosis are exploited by cancer cells to acquire nutrients and reprogram metabolism, and blocking or reversing this uptake can alter tumor growth and survival. The term also connects to renal physiology, where endocytic receptors such as megalin depend on endolysosomal transporters like Spns1, and to macrophage biology, where Src-family kinases and Akt3 tune fluid-phase and receptor-mediated uptake. Understanding which genes enforce the negative regulation of pinocytosis therefore provides both mechanistic insight and candidate therapeutic targets. This article synthesizes the QuickGO definition of GO:0048550 with verified PubMed literature to describe the signaling, trafficking, and disease contexts of negative regulation of pinocytosis, and to outline the CRISPR-based experimental models used to dissect it.
negative regulation of pinocytosis At A Glance
| GO ID | GO:0048550 |
|---|---|
| GO term | negative regulation of pinocytosis |
| Ontology | biological_process |
| Synonym | down regulation of pinocytosis; down-regulation of pinocytosis; downregulation of pinocytosis; inhibition of pinocytosis |
| Definition | Any process that stops, prevents, or reduces the frequency, rate or extent of pinocytosis, the 'cell drinking' uptake of extracellular fluid into vesicles that deliver contents to endosomes |
| Major function | Suppression or dampening of fluid-phase uptake, thereby limiting nutrient acquisition, membrane turnover, and downstream endosomal signaling |
| Related process | Macropinocytosis, a related actin-driven fluid-phase uptake pathway frequently studied alongside pinocytosis in cancer and immune cells |
| Key regulators | PI3K/PTEN, Akt3, PAK1, mTORC1, Src-family kinases, and endolysosomal transporters such as Spns1 |
| Disease relevance | Cancer nutrient acquisition, metabolic reprogramming, renal endocytic disorders, and macrophage-mediated immunity |
What Is GO:0048550?
Negative regulation of pinocytosis (GO:0048550) is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of pinocytosis. Pinocytosis itself is the process in which cells take in liquid material from their external environment, literally 'cell drinking'; the liquid is enclosed in vesicles formed by invagination of the plasma membrane, and these vesicles then move into the cell and pass their contents to endosomes. In practical terms, GO:0048550 annotates gene products and pathways that act as brakes on this fluid-phase uptake route, whether by dampening the signaling that triggers membrane ruffling, by altering the actin cytoskeleton, or by changing the endosomal trafficking that sustains uptake.
Why Is negative regulation of pinocytosis Important in Cell Biology?
Negative regulation of pinocytosis is important because fluid-phase uptake is a double-edged sword: it supplies cells with nutrients and lipids, but when unchecked it supports cancer cell survival, metabolic reprogramming, and therapeutic resistance. Identifying the genes and signals that enforce this negative regulation reveals how normal cells restrain 'cell drinking' and how tumors bypass those brakes. The term also matters for renal and immune physiology, where endocytic receptors and Src-family kinases set the threshold for uptake, and for drug delivery, because the rate of pinocytosis determines how much extracellular material reaches endosomes.
• Defines the molecular brakes on fluid-phase uptake, a core nutrient-acquisition route in cancer cells.
• Connects PI3K/PTEN signaling to macropinocytosis and pinocytosis control in pancreatic cancer and other tumors.
• Links Akt3 and the WNK/SGK1/Cdc42 pathway to suppression of low-density lipoprotein pinocytosis in macrophages.
• Positions p21-activated kinase-1 (PAK1) as a regulator of macropinocytosis, a process closely related to pinocytosis.
• Ties mTORC1 and cellular growth control to fluid-phase uptake and lysosomal nutrient sensing.
• Implicates Src-family kinase Fgr in negative regulation of phagocytosis, informing how kinase brakes shape myeloid uptake.
• Highlights Spns1 as an endolysosomal transporter essential for megalin-dependent endocytosis in renal cells.
• Provides a framework for therapeutic targeting of uptake pathways in cancer and metabolic disease.
• Guides CRISPR model design for testing causal roles of candidate genes in pinocytosis.
• Supports drug-delivery research by quantifying how much extracellular cargo enters endosomes.
What Happens During negative regulation of pinocytosis?
Initiation and membrane ruffling are dampened
In simple terms: The cell first has to start drinking; negative regulation works by turning down the signals that tell the membrane to ruffle and fold inward.
Pinocytosis begins with plasma membrane invagination and vesicle formation, and negative regulation of pinocytosis acts at this earliest step by reducing the signaling that triggers membrane ruffling and vesicle budding. Actin dynamics are central to this step, and unconventional myosins contribute to the membrane and cargo movements that underlie uptake, so their modulation can restrain the initiation of fluid-phase uptake. In cancer cells, constitutive PI3K signaling driven by PTEN oxidation promotes macropinocytosis, and reversing this signal restores a more restrained uptake state.
Small GTPase and kinase switches set the threshold
In simple terms: Molecular switches decide whether the cell keeps drinking or stops; negative regulation flips these switches toward 'stop'.
Small GTPases and their effectors set the threshold for fluid-phase uptake. p21-activated kinase-1 (PAK1) regulates macropinocytosis, and its activity is required for the membrane dynamics that support uptake, so reducing PAK1 signaling suppresses this route. Akt3 kinase suppresses pinocytosis of low-density lipoprotein by macrophages via a WNK/SGK1/Cdc42 protein pathway, providing a direct example of a kinase that negatively regulates a pinocytic cargo. Src-family kinases such as Fgr negatively regulate phagocytosis in murine macrophages, illustrating how kinase brakes can shape related myeloid uptake processes.
mTORC1 and nutrient sensing feed back on uptake
In simple terms: The cell's nutrient sensor can tell it to slow down drinking when resources are already sufficient.
Macropinocytosis, mTORC1, and cellular growth control are functionally linked, with mTORC1 integrating nutrient availability and growth signals that influence fluid-phase uptake. Because pinocytosis delivers extracellular fluid to endosomes and lysosomes, the resulting nutrient flux can feed back on mTORC1, and negative regulation of pinocytosis can therefore be part of a homeostatic loop that prevents excessive uptake when nutrients are plentiful. This feedback positions mTORC1 as both a sensor and an effector in the negative regulation of pinocytosis.
Endosomal trafficking and lysosomal transporters constrain uptake
In simple terms: Once the cell has swallowed fluid, the recycling and transporter machinery decides whether it keeps drinking or slows down.
After vesicles form, their contents pass to endosomes, and the efficiency of this trafficking influences the overall rate of pinocytosis. Spns1 is an iron transporter essential for megalin-dependent endocytosis, linking endolysosomal transport to the endocytic machinery that pinocytosis feeds. Negative regulation of pinocytosis can therefore arise from constraints on endosomal maturation, cargo sorting, or lysosomal function that make continued uptake energetically or functionally unfavorable.
Cytoskeletal and membrane remodeling enforces the brake
In simple terms: The cell's internal skeleton and membrane recycling system can physically put the brakes on drinking.
Unconventional myosins participate in membrane and cargo movements, and their regulation can influence the membrane remodeling required for vesicle formation during pinocytosis. Because pinocytosis depends on invagination of the plasma membrane and vesicle movement into the cell, negative regulation can be enforced by limiting the availability of membrane, by altering actin-based motility, or by changing the balance of endocytic and exocytic recycling. These cytoskeletal constraints provide a physical layer of negative regulation on top of the signaling brakes.
Key Genes Involved in GO:0048550 negative regulation of pinocytosis
The following genes and proteins have been experimentally linked to pinocytosis, macropinocytosis, or related endocytic uptake processes and are therefore relevant to the study of GO:0048550.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTEN | Lipid phosphatase that opposes PI3K signaling; its oxidation promotes constitutive PI3K signaling and inducible macropinocytosis | Tumor suppressor whose loss or oxidation drives fluid-phase uptake in pancreatic cancer |
| PIK3CA/PI3K | Generates PIP3 to promote membrane ruffling and macropinocytosis | Central driver of uptake that negative regulators such as PTEN restrain |
| AKT3 | Kinase that suppresses pinocytosis of low-density lipoprotein via WNK/SGK1/Cdc42 | Direct negative regulator of a pinocytic cargo in macrophages |
| WNK1 | Kinase in the WNK/SGK1/Cdc42 pathway downstream of Akt3 | Component of the signaling brake on macrophage pinocytosis |
| SGK1 | Serum- and glucocorticoid-regulated kinase in the Akt3/WNK pathway | Effector linking Akt3 to Cdc42 and pinocytosis suppression |
| CDC42 | Rho-family GTPase controlling actin dynamics and uptake | Downstream node through which Akt3 suppresses pinocytosis |
| PAK1 | p21-activated kinase-1 that regulates macropinocytosis | Positive regulator of uptake whose inhibition reduces fluid-phase internalization |
| MTOR | mTORC1 kinase integrating nutrient and growth signals | Links nutrient sensing and growth control to macropinocytosis |
| FGR | Src-family kinase that negatively regulates phagocytosis in murine macrophages | Model for kinase-mediated negative regulation of myeloid uptake |
| SPNS1 | Endolysosomal iron transporter essential for megalin-dependent endocytosis | Connects lysosomal transport to endocytic uptake in renal cells |
| LRP2/Megalin | Endocytic receptor whose function depends on Spns1 | Readout for endocytic capacity in kidney models |
| MYO5A | Unconventional myosin involved in membrane and cargo movement | Cytoskeletal contributor to membrane remodeling during uptake |
| MYO6 | Unconventional myosin implicated in endocytic trafficking | Candidate for modulating vesicle movement during pinocytosis |
| MYO7A | Unconventional myosin with roles in membrane trafficking | Potential modifier of endocytic membrane dynamics |
| RAC1 | Rho-family GTPase promoting membrane ruffling | Upstream activator of macropinocytic uptake |
| SRC | Non-receptor tyrosine kinase family member | Family context for Fgr-mediated negative regulation of uptake |
| RPTOR | Core component of mTORC1 | Scaffold for mTORC1-dependent control of growth and uptake |
| LAMP1 | Lysosomal marker used to track endocytic cargo | Readout for endosomal/lysosomal delivery after pinocytosis |
How Is negative regulation of pinocytosis Regulated?
Negative regulation of pinocytosis is controlled by layered signaling and trafficking inputs. PI3K/PTEN signaling sets the level of PIP3 that drives membrane ruffling, and PTEN oxidation promotes constitutive PI3K signaling and inducible macropinocytosis in pancreatic cancer, so restoring PTEN function or inhibiting PI3K restrains uptake. Akt3 suppresses pinocytosis of low-density lipoprotein by macrophages through a WNK/SGK1/Cdc42 pathway, providing a kinase cascade that directly brakes a pinocytic route. PAK1 regulates macropinocytosis, and its activity is required for the membrane dynamics of uptake, so reducing PAK1 signaling suppresses this process. mTORC1 integrates nutrient and growth signals with macropinocytosis, forming a feedback loop in which uptake-derived nutrients influence growth control. Src-family kinases such as Fgr negatively regulate phagocytosis in murine macrophages, illustrating how kinase brakes can shape related myeloid uptake processes. Finally, endolysosomal transporters such as Spns1 are required for megalin-dependent endocytosis, linking lysosomal function to the endocytic machinery that pinocytosis feeds.
negative regulation of pinocytosis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTEN | Pancreatic cancer with constitutive PI3K signaling and inducible macropinocytosis | PTEN knockout or oxidation-mimetic knock-in in pancreatic cancer cell lines |
| AKT3 | Macrophage lipoprotein pinocytosis and lipid handling | Akt3 knockout and point-mutation macrophages with LDL uptake assays |
| SPNS1 | Renal megalin-dependent endocytosis and endolysosomal transport | Spns1 knockout renal epithelial cells with megalin uptake readouts |
| PAK1 | Macropinocytosis-dependent cancer growth | PAK1 knockout and kinase-dead knock-in cells with fluid-phase uptake assays |
| FGR | Myeloid phagocytosis and immune uptake regulation | Fgr knockout murine macrophages with phagocytosis and pinocytosis assays |
Cancer nutrient acquisition and metabolic reprogramming
Cancer cells use macropinocytosis and related fluid-phase uptake to acquire nutrients and reprogram metabolism, and negative regulation of pinocytosis is therefore a barrier that tumors must overcome. In pancreatic cancer, PTEN oxidation promotes constitutive PI3K signaling and inducible macropinocytosis, linking loss of a negative regulator to enhanced uptake and tumor growth. Targeting the signaling nodes that restrain pinocytosis, such as PI3K/PTEN and PAK1, is an active therapeutic strategy in cancers that depend on fluid-phase uptake.
Renal endocytic disorders and megalin-dependent uptake
In the kidney, endocytic receptors such as megalin mediate the reabsorption of filtered proteins, and this process depends on endolysosomal transporters including Spns1. Spns1 is an iron transporter essential for megalin-dependent endocytosis, so its dysfunction impairs endocytic capacity and can contribute to renal phenotypes. Negative regulation of pinocytosis is relevant here because the same endosomal trafficking machinery constrains both receptor-mediated and fluid-phase uptake.
Macrophage biology, immunity, and lipoprotein handling
Macrophages use pinocytosis and related uptake routes to sample their environment and handle lipoproteins, and Akt3 suppresses pinocytosis of low-density lipoprotein via a WNK/SGK1/Cdc42 pathway. Src-family kinases such as Fgr negatively regulate phagocytosis in murine macrophages, showing that kinase brakes shape myeloid uptake programs. Dysregulation of these brakes can alter lipid accumulation and immune responses, making negative regulation of pinocytosis relevant to atherosclerosis and inflammatory disease.
Metabolic and growth-control disorders
mTORC1 links nutrient sensing, cellular growth control, and macropinocytosis, so perturbations in this axis can affect both uptake and metabolism. Because pinocytosis delivers extracellular fluid to endosomes and lysosomes, changes in its negative regulation can influence nutrient availability and growth signaling, with implications for metabolic disease and tissue growth disorders.
From negative regulation of pinocytosis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for negative regulation of pinocytosis? | CRISPR knockout of the gene in a cell line with a fluorescent fluid-phase uptake assay |
| Does a specific phosphorylation site control the brake on pinocytosis? | Point-mutation knock-in of the phospho-dead or phospho-mimetic residue |
| Does a disease-associated variant alter uptake? | Knock-in of the patient variant and comparison with wild type |
| Where does the regulator localize during uptake? | Tagged knock-in with fluorescent or epitope tag and live imaging |
| Does overexpression of a brake reduce uptake? | Overexpression of the candidate gene and quantification of fluid-phase uptake |
| Which genes modify pinocytosis at scale? | CRISPR library screening with an uptake-based selection |
How to Study the negative regulation of pinocytosis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Fluorescent dextran uptake | Rate of fluid-phase pinocytosis | Quantifying negative regulation in CRISPR-perturbed cells |
| Labeled LDL uptake | Receptor-independent and receptor-dependent lipoprotein pinocytosis | Macrophage lipid handling and Akt3 pathway studies |
| Live-cell imaging | Membrane ruffling, vesicle formation, and endosomal delivery | Localizing where a brake acts in the pathway |
| Phosphoproteomics | Kinase-dependent phosphorylation changes | Mapping PI3K, Akt3, and PAK1 signaling to uptake |
| CRISPR library screening | Genes that modify pinocytosis at scale | Discovery of negative regulators and modifiers |
| Endocytic cargo tracking | Delivery of cargo to endosomes and lysosomes | Assessing endosomal trafficking constraints on uptake |
| Metabolic flux analysis | Nutrient acquisition and metabolic reprogramming | Linking uptake to cancer metabolism |
| Immunofluorescence of endosomal markers | Endosomal and lysosomal composition | Validating trafficking changes after perturbation |
Fluid-phase uptake assays
Fluid-phase uptake assays using fluorescent dextran or labeled low-density lipoprotein quantify the rate of pinocytosis and its suppression by candidate negative regulators. These assays are typically combined with CRISPR perturbation to test causality, and they can be adapted to macrophages, cancer cells, and renal epithelial cells.
Live-cell imaging and membrane dynamics
Live-cell imaging of membrane ruffling, vesicle formation, and endosomal delivery reveals where a negative regulator acts within the pinocytic pathway. Unconventional myosins and actin dynamics can be visualized to determine whether the brake operates at initiation, vesicle movement, or endosomal trafficking.
Signaling and phosphoproteomics
Phosphoproteomics and pathway analysis identify the kinase cascades, such as PI3K/PTEN, Akt3/WNK/SGK1/Cdc42, and PAK1, that enforce negative regulation of pinocytosis. These methods connect a candidate gene to the signaling nodes that set the uptake threshold.
CRISPR screening and functional genomics
CRISPR library screening with an uptake-based readout identifies genes whose loss increases or decreases pinocytosis, providing a systematic map of negative regulators. Hits can then be validated individually with knockout, point-mutation, and overexpression models.
How CRISPR Can Be Used to Study GO:0048550 negative regulation of pinocytosis
Knockout
CRISPR knockout of candidate genes is used to test whether a factor is required for negative regulation of pinocytosis; loss of a brake is expected to increase fluid-phase uptake, as seen for regulators such as PTEN and Akt3. Knockout models are also used to validate hits from CRISPR library screens and to confirm specificity with multiple guide RNAs.
Point Mutation
Point-mutation knock-in of phospho-dead or phospho-mimetic residues tests whether specific phosphorylation sites control the brake on pinocytosis, as illustrated by PTEN oxidation and Akt3 pathway studies. These models distinguish catalytic activity from regulatory post-translational control.
Knock-in
Knock-in of disease-associated variants or fluorescent tags allows researchers to compare wild-type and mutant alleles in the same cellular context and to visualize the regulator during uptake. Tagged knock-in lines are particularly useful for live imaging of endosomal trafficking.
Overexpression
Overexpression of a candidate negative regulator is used to test whether increased dosage reduces pinocytosis, complementing loss-of-function experiments. Overexpression models are also used to probe mTORC1-dependent growth control and PAK1-driven macropinocytosis.
How EDITGENE Supports negative regulation of pinocytosis Research
Researchers studying negative regulation of pinocytosis-related genes often need to determine whether a candidate gene is causally involved in setting the uptake threshold, and CRISPR-based models provide the most direct way to test this. EDITGENE supports this work with knockout, point-mutation, knock-in, overexpression cell models, and CRISPR library screening combined with bioinformatics, so that hypotheses about GO:0048550 can be tested in physiologically relevant systems.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of pinocytosis research.
Frequently Asked Questions About negative regulation of pinocytosis
What is negative regulation of pinocytosis (GO:0048550)?
It is any process that stops, prevents, or reduces the frequency, rate, or extent of pinocytosis, the 'cell drinking' uptake of extracellular fluid into vesicles that deliver contents to endosomes.
What genes are involved in negative regulation of pinocytosis?
Genes implicated in restraining fluid-phase uptake include PTEN, AKT3, WNK1, SGK1, CDC42, and FGR, while PAK1 and mTORC1 modulate related macropinocytic uptake.
How is pinocytosis different from macropinocytosis?
Pinocytosis is the general fluid-phase uptake of liquid into vesicles formed by plasma membrane invagination, whereas macropinocytosis is a related actin-driven uptake route frequently studied alongside it in cancer and immune cells.
Why is negative regulation of pinocytosis important in cancer?
Cancer cells use macropinocytosis and fluid-phase uptake for nutrient acquisition and metabolic reprogramming, so the brakes on these processes must be overcome for tumors to grow.
Which signaling pathways control pinocytosis?
PI3K/PTEN, Akt3 with WNK/SGK1/Cdc42, PAK1, and mTORC1 are among the pathways that set the threshold for pinocytosis and macropinocytosis.
How do researchers measure negative regulation of pinocytosis?
Common methods include fluorescent dextran or labeled LDL uptake assays, live-cell imaging of membrane dynamics, phosphoproteomics, and CRISPR library screening.
What is the role of Akt3 in pinocytosis?
Akt3 kinase suppresses pinocytosis of low-density lipoprotein by macrophages via a WNK/SGK1/Cdc42 protein pathway.
How does PTEN affect macropinocytosis?
PTEN oxidation promotes constitutive PI3K signaling and inducible macropinocytosis in pancreatic cancer, linking loss of a negative regulator to increased uptake.
What is the role of Spns1 in endocytosis?
Spns1 is an iron transporter essential for megalin-dependent endocytosis, connecting endolysosomal transport to the endocytic machinery that pinocytosis feeds.
How can CRISPR be used to study negative regulation of pinocytosis?
CRISPR knockout, point-mutation, knock-in, and overexpression models, together with CRISPR library screening, allow causal testing of candidate genes that restrain fluid-phase uptake.
Conclusion
GO:0048550, negative regulation of pinocytosis, defines the cellular brakes on fluid-phase uptake, a process that supplies nutrients and shapes signaling through endosomal delivery. The verified literature links these brakes to PI3K/PTEN, Akt3/WNK/SGK1/Cdc42, PAK1, mTORC1, Src-family kinases, and endolysosomal transporters such as Spns1, with direct implications for cancer, renal endocytic disorders, and macrophage biology. Because dysregulated pinocytosis supports tumor nutrient acquisition and metabolic reprogramming, understanding its negative regulation offers both mechanistic insight and therapeutic opportunities. CRISPR-based knockout, point-mutation, knock-in, overexpression, and library-screening models provide the experimental toolkit needed to move from correlation to causation in this pathway.
References
- 1. Xu G et al.. 2025. Survival strategies of cancer cells: the role of macropinocytosis in nutrient acquisition, metabolic reprogramming, and therapeutic targeting.. Autophagy 21(4):693-718 PMID: 39817564
- 2. Beenken A et al.. 2024. Spns1 is an iron transporter essential for megalin-dependent endocytosis.. Am J Physiol Renal Physiol 327(5):F775-F787 PMID: 39265081
- 3. Gresham HD et al.. 2000. Negative regulation of phagocytosis in murine macrophages by the Src kinase family member, Fgr.. J Exp Med 191(3):515-28 PMID: 10662797
- 4. Kalhammer G et al.. 2000. Unconventional myosins.. Essays Biochem 35:33-42 PMID: 12471888
- 5. Burge RA et al.. 2026. PTEN Oxidation Promotes Constitutive PI3K Signaling and Inducible Macropinocytosis in Pancreatic Cancer.. Cancer Res 86(8):1854-1867 PMID: 41134579
- 6. Dharmawardhane S et al.. 2000. Regulation of macropinocytosis by p21-activated kinase-1.. Mol Biol Cell 11(10):3341-52 PMID: 11029040
- 7. Yoshida S et al.. 2018. Macropinocytosis, mTORC1 and cellular growth control.. Cell Mol Life Sci 75(7):1227-1239 PMID: 29119228
- 8. Ding L et al.. 2017. Akt3 kinase suppresses pinocytosis of low-density lipoprotein by macrophages via a novel WNK/SGK1/Cdc42 protein pathway.. J Biol Chem 292(22):9283-9293 PMID: 28389565
